Strategy Protalix is a leading biologic drug company with a next-generation expression technology, ProCellEx, to access the exploding area of biosimilars, biobetters and novel biologics – a potential market of $125+ billion. The ProCellEx platform technology potentially offers significant advantages over existing expression systems, including cost effectiveness, safety and entry into certain patent-protected markets.
The first drug, waiting for approval this week, is targeting a $1.25B (not 125) market.
Adjust your expectations. There will be no $1B yearly revenues from this drug:
1. - We are not going to take 100% of the market. Shire and Sanofi/Genzime will find ways to retain varying percentages of their respective patient bases. There are going to be three players, no one takes all.
2. - We are going to be cheaper than the other players (good for the patients and the insurers). The size of the market will shrink accordingly.
3. - Pfizer will take 60% of the revenues from sales outside of Israel.
Our CEO is Dr. "David" (not yet "Goliath") Aviezer.
The approval of the Gaucher drug will only open a tap. The big flood will come later, as the pipeline comes to age.